DelistingMay 15, 2026, 04:52 PM
Glucotrack Faces Nasdaq Delisting for Bid Price & Equity
AI Summary
Glucotrack, Inc. received two separate notices from Nasdaq regarding non-compliance with listing rules. The first, on May 11, 2026, cited failure to maintain a minimum bid price of $1.00 per share. The second, on May 15, 2026, indicated the company no longer meets the $2,500,000 minimum stockholders' equity requirement, nor its alternatives. Glucotrack intends to request a hearing by May 18, 2026, to appeal these delisting determinations, which will stay further delisting actions.
Key Highlights
- Glucotrack received a Staff Determination letter on May 11, 2026, for not complying with Nasdaq's $1.00 minimum bid price rule (Rule 5550(a)(2)).
- The company intends to request a hearing by May 18, 2026, to appeal Nasdaq Staff's delisting determination.
- A timely hearing request will stay further delisting actions through the hearing process.
- On May 15, 2026, Glucotrack received a second letter from Nasdaq for not meeting the $2,500,000 minimum stockholders' equity requirement (Rule 5550(b)(1)).
- The company also does not meet alternative requirements for market value of listed securities or net income.
- Failure to meet the minimum stockholders' equity requirement is an additional basis for delisting.
- Glucotrack plans to present its views on this additional deficiency to the Panel at its hearing.
Price Impact
More from GCTK